| Brain targeting of a water insoluble antipsychotic drug haloperidol via the intranasal route using PAMAM dendrimer YK Katare, RP Daya, C Sookram Gray, RE Luckham, J Bhandari, ... Molecular pharmaceutics 12 (9), 3380-3388, 2015 | 103 | 2015 |
| Haloperidol-loaded intranasally administered lectin functionalized poly (ethylene glycol)–block-poly (d, l)-lactic-co-glycolic acid (PEG–PLGA) nanoparticles for the treatment … J Piazza, T Hoare, L Molinaro, K Terpstra, J Bhandari, ... European Journal of Pharmaceutics and Biopharmaceutics 87 (1), 30-39, 2014 | 94 | 2014 |
| Intranasal delivery of antipsychotic drugs YK Katare, JE Piazza, J Bhandari, RP Daya, K Akilan, MJ Simpson, ... Schizophrenia Research 184, 2-13, 2017 | 56 | 2017 |
| Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization D Basu, Y Tian, J Bhandari, JR Jiang, P Hui, RL Johnson, RK Mishra PLoS One 8 (8), e70736, 2013 | 22 | 2013 |
| Improvements and important considerations for the 5-choice serial reaction time task—An effective measurement of visual attention in rats J Bhandari, R Daya, RK Mishra Journal of Neuroscience Methods 270, 17-29, 2016 | 19 | 2016 |
| Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function utilizing PET and CT fused imaging in live rats RP Daya, JK Bhandari, PA Hui, Y Tian, T Farncombe, RK Mishra Neuropharmacology 77, 325-333, 2014 | 18 | 2014 |
| The dopamine allosteric agent, PAOPA, demonstrates therapeutic potential in the phencyclidine NMDA pre-clinical rat model of schizophrenia RP Daya, J Bhandari, SK Kooner, J Ho, CD Rowley, NA Bock, ... Frontiers in Behavioral Neuroscience 12, 302, 2018 | 9 | 2018 |
| Change in expression of vesicular protein synapsin II by chronic treatment with D2 allosteric modulator PAOPA D Basu, Y Tian, P Hui, J Bhandari, RL Johnson, RK Mishra Peptides 66, 58-62, 2015 | 2 | 2015 |
| Effect of Chronic Treatment with D2 Allosteric Modulator PAOPA on the Expression of Cerebral Dopamine Neurotrophic Factor (CDNF) in Select Brain Regions Y Tian, R Daya, J Bhandari, H Joshi, S Thomson, V Patel, R Mishra International Journal of Peptide Research and Therapeutics 27 (4), 2551-2557, 2021 | | 2021 |
| The Effect of PAOPA, a Novel Allosteric Modulator of Dopamine D2 Receptors, on Signaling Proteins Following Sub-Chronic Administration in Rats R Daya, J Ho, S Thomson, J Bhandari, RK Mishra Current Molecular Pharmacology 14 (4), 469-476, 2021 | | 2021 |
| Characterizing the cognitive, behavioural, and mechanistic actions of novel allosteric modulator PAOPA for the treatment of schizophrenia J Bhandari | | 2015 |
| Compound 186 is a Negative Allosteric Modulator of Dopamine D2 Receptors: Implications for Improving Schizophrenia Therapy J Bhandari, J Mah, R Daya, RL Johnson, RK Mishra The Meducator 1 (22), 2012 | | 2012 |
| PAMAM dendrimer based formulation of haloperidol for brain targeting via intranasal delivery YK Katare, RP Daya, C Sookram, R Luckham, J Bhandari, AS Chauhan, ... | | |
| MACABSTRACTS R dAMAgEd AdulT SEnSoRy nEuRonS In, S ThERApy | | |
Todd HoareDepartment of Chemical Engineering, McMaster UniversityVerified email at mcmaster.ca
